TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07861126: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Assess the Efficacy and Safety of Sovateltide in Patients With Traumatic Brain Injury

Sponsor: Pharmazz, Inc. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 214 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT07861126 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07861126 Rescue Dossier →